Rise Therapeutics Receives FDA IND Clearance To Initiate Clinical Testing of R-5780 in Cancer

UF startup Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a cancer Phase 1 clinical trial for its program candidate, R-5780. This is Rise Therapeutics’ fourth clinical program to enter patient clinical testing. For separate products, other clinical studies are ongoing for the treatment of ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.